Cargando…

Analysis of the Fibrinogen and Neutrophil–Lymphocyte Ratio in Esophageal Squamous Cell Carcinoma: A Promising Blood Marker of Tumor Progression and Prognosis

Esophageal squamous cell carcinoma (ESCC) is one of the most aggressive malignancies in gastrointestinal tract cancers and even patients with early ESCC have a high metastatic potential. Difficulties are associated with clinically predicting tumor progression and prognosis based on conventional tumo...

Descripción completa

Detalles Bibliográficos
Autores principales: Arigami, Takaaki, Okumura, Hiroshi, Matsumoto, Masataka, Uchikado, Yasuto, Uenosono, Yoshikazu, Kita, Yoshiaki, Owaki, Tetsuhiro, Mori, Shinichiro, Kurahara, Hiroshi, Kijima, Yuko, Ishigami, Sumiya, Natsugoe, Shoji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4620830/
https://www.ncbi.nlm.nih.gov/pubmed/26496280
http://dx.doi.org/10.1097/MD.0000000000001702
_version_ 1782397364364902400
author Arigami, Takaaki
Okumura, Hiroshi
Matsumoto, Masataka
Uchikado, Yasuto
Uenosono, Yoshikazu
Kita, Yoshiaki
Owaki, Tetsuhiro
Mori, Shinichiro
Kurahara, Hiroshi
Kijima, Yuko
Ishigami, Sumiya
Natsugoe, Shoji
author_facet Arigami, Takaaki
Okumura, Hiroshi
Matsumoto, Masataka
Uchikado, Yasuto
Uenosono, Yoshikazu
Kita, Yoshiaki
Owaki, Tetsuhiro
Mori, Shinichiro
Kurahara, Hiroshi
Kijima, Yuko
Ishigami, Sumiya
Natsugoe, Shoji
author_sort Arigami, Takaaki
collection PubMed
description Esophageal squamous cell carcinoma (ESCC) is one of the most aggressive malignancies in gastrointestinal tract cancers and even patients with early ESCC have a high metastatic potential. Difficulties are associated with clinically predicting tumor progression and prognosis based on conventional tumor markers determined from preoperative blood examinations. The aim of the present study was to measure plasma fibrinogen levels and the neutrophil–lymphocyte ratio (NLR) in blood and compare the clinical impacts of their combined values (fibrinogen and neutrophil–lymphocyte ratio score—F-NLR score) and the modified Glasgow Prognostic Score (mGPS) in patients with ESCC. We classified 238 patients with ESCC based on cut-off values for hyperfibrinogenemia (>400 mg/dL) and high NLR (>3.0) as F-NLR scores of 2 (both of these hematological abnormalities), 1 (one of these abnormalities), or 0 (neither abnormality). We also categorized patients based on cut-off values for high C-reactive protein (CRP) (>0.5 mg/dL) and hypoalbuminemia (<3.8 g/dL) as mGPS of 2 (elevated CRP and hypoalbuminemia), 1 (either elevated CRP or hypoalbuminemia), or 0 (neither elevated CRP nor hypoalbuminemia). The F-NLR score correlated with the depth of tumor invasion, lymph node metastasis, lymphovascular invasion, tumor size, and stage (all P < 0.05). Prognoses among the groups based on the F-NLR score and mGPS significantly differed (all P < 0.001). A multivariate analysis identified the depth of tumor invasion, lymph node metastasis, and F-NLR score as independent prognostic factors (P = 0.002, P = 0.007, and P = 0.037, respectively). The results of the present study showed that the F-NLR score is a promising blood predictor for tumor progression and outcomes in patients with ESCC.
format Online
Article
Text
id pubmed-4620830
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-46208302015-10-27 Analysis of the Fibrinogen and Neutrophil–Lymphocyte Ratio in Esophageal Squamous Cell Carcinoma: A Promising Blood Marker of Tumor Progression and Prognosis Arigami, Takaaki Okumura, Hiroshi Matsumoto, Masataka Uchikado, Yasuto Uenosono, Yoshikazu Kita, Yoshiaki Owaki, Tetsuhiro Mori, Shinichiro Kurahara, Hiroshi Kijima, Yuko Ishigami, Sumiya Natsugoe, Shoji Medicine (Baltimore) 4500 Esophageal squamous cell carcinoma (ESCC) is one of the most aggressive malignancies in gastrointestinal tract cancers and even patients with early ESCC have a high metastatic potential. Difficulties are associated with clinically predicting tumor progression and prognosis based on conventional tumor markers determined from preoperative blood examinations. The aim of the present study was to measure plasma fibrinogen levels and the neutrophil–lymphocyte ratio (NLR) in blood and compare the clinical impacts of their combined values (fibrinogen and neutrophil–lymphocyte ratio score—F-NLR score) and the modified Glasgow Prognostic Score (mGPS) in patients with ESCC. We classified 238 patients with ESCC based on cut-off values for hyperfibrinogenemia (>400 mg/dL) and high NLR (>3.0) as F-NLR scores of 2 (both of these hematological abnormalities), 1 (one of these abnormalities), or 0 (neither abnormality). We also categorized patients based on cut-off values for high C-reactive protein (CRP) (>0.5 mg/dL) and hypoalbuminemia (<3.8 g/dL) as mGPS of 2 (elevated CRP and hypoalbuminemia), 1 (either elevated CRP or hypoalbuminemia), or 0 (neither elevated CRP nor hypoalbuminemia). The F-NLR score correlated with the depth of tumor invasion, lymph node metastasis, lymphovascular invasion, tumor size, and stage (all P < 0.05). Prognoses among the groups based on the F-NLR score and mGPS significantly differed (all P < 0.001). A multivariate analysis identified the depth of tumor invasion, lymph node metastasis, and F-NLR score as independent prognostic factors (P = 0.002, P = 0.007, and P = 0.037, respectively). The results of the present study showed that the F-NLR score is a promising blood predictor for tumor progression and outcomes in patients with ESCC. Wolters Kluwer Health 2015-10-23 /pmc/articles/PMC4620830/ /pubmed/26496280 http://dx.doi.org/10.1097/MD.0000000000001702 Text en Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved. http://creativecommons.org/licenses/by/4.0 This is an open access article distributed under the Creative Commons Attribution License 4.0, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0
spellingShingle 4500
Arigami, Takaaki
Okumura, Hiroshi
Matsumoto, Masataka
Uchikado, Yasuto
Uenosono, Yoshikazu
Kita, Yoshiaki
Owaki, Tetsuhiro
Mori, Shinichiro
Kurahara, Hiroshi
Kijima, Yuko
Ishigami, Sumiya
Natsugoe, Shoji
Analysis of the Fibrinogen and Neutrophil–Lymphocyte Ratio in Esophageal Squamous Cell Carcinoma: A Promising Blood Marker of Tumor Progression and Prognosis
title Analysis of the Fibrinogen and Neutrophil–Lymphocyte Ratio in Esophageal Squamous Cell Carcinoma: A Promising Blood Marker of Tumor Progression and Prognosis
title_full Analysis of the Fibrinogen and Neutrophil–Lymphocyte Ratio in Esophageal Squamous Cell Carcinoma: A Promising Blood Marker of Tumor Progression and Prognosis
title_fullStr Analysis of the Fibrinogen and Neutrophil–Lymphocyte Ratio in Esophageal Squamous Cell Carcinoma: A Promising Blood Marker of Tumor Progression and Prognosis
title_full_unstemmed Analysis of the Fibrinogen and Neutrophil–Lymphocyte Ratio in Esophageal Squamous Cell Carcinoma: A Promising Blood Marker of Tumor Progression and Prognosis
title_short Analysis of the Fibrinogen and Neutrophil–Lymphocyte Ratio in Esophageal Squamous Cell Carcinoma: A Promising Blood Marker of Tumor Progression and Prognosis
title_sort analysis of the fibrinogen and neutrophil–lymphocyte ratio in esophageal squamous cell carcinoma: a promising blood marker of tumor progression and prognosis
topic 4500
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4620830/
https://www.ncbi.nlm.nih.gov/pubmed/26496280
http://dx.doi.org/10.1097/MD.0000000000001702
work_keys_str_mv AT arigamitakaaki analysisofthefibrinogenandneutrophillymphocyteratioinesophagealsquamouscellcarcinomaapromisingbloodmarkeroftumorprogressionandprognosis
AT okumurahiroshi analysisofthefibrinogenandneutrophillymphocyteratioinesophagealsquamouscellcarcinomaapromisingbloodmarkeroftumorprogressionandprognosis
AT matsumotomasataka analysisofthefibrinogenandneutrophillymphocyteratioinesophagealsquamouscellcarcinomaapromisingbloodmarkeroftumorprogressionandprognosis
AT uchikadoyasuto analysisofthefibrinogenandneutrophillymphocyteratioinesophagealsquamouscellcarcinomaapromisingbloodmarkeroftumorprogressionandprognosis
AT uenosonoyoshikazu analysisofthefibrinogenandneutrophillymphocyteratioinesophagealsquamouscellcarcinomaapromisingbloodmarkeroftumorprogressionandprognosis
AT kitayoshiaki analysisofthefibrinogenandneutrophillymphocyteratioinesophagealsquamouscellcarcinomaapromisingbloodmarkeroftumorprogressionandprognosis
AT owakitetsuhiro analysisofthefibrinogenandneutrophillymphocyteratioinesophagealsquamouscellcarcinomaapromisingbloodmarkeroftumorprogressionandprognosis
AT morishinichiro analysisofthefibrinogenandneutrophillymphocyteratioinesophagealsquamouscellcarcinomaapromisingbloodmarkeroftumorprogressionandprognosis
AT kuraharahiroshi analysisofthefibrinogenandneutrophillymphocyteratioinesophagealsquamouscellcarcinomaapromisingbloodmarkeroftumorprogressionandprognosis
AT kijimayuko analysisofthefibrinogenandneutrophillymphocyteratioinesophagealsquamouscellcarcinomaapromisingbloodmarkeroftumorprogressionandprognosis
AT ishigamisumiya analysisofthefibrinogenandneutrophillymphocyteratioinesophagealsquamouscellcarcinomaapromisingbloodmarkeroftumorprogressionandprognosis
AT natsugoeshoji analysisofthefibrinogenandneutrophillymphocyteratioinesophagealsquamouscellcarcinomaapromisingbloodmarkeroftumorprogressionandprognosis